



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Camellia W. Adams et al.

Serial No.: 10/614,959

Filed: July 8, 2003

For: HUMAN ANTI-FACTOR IX/IXa ANTI

BODIES

Group Art Unit: 1644

Examiner: to be assigned

Confirmation No: 7129

Customer No: 09157

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

January 23, 2004

Christine Ricks

REQUEST FOR A CORRECTED FILING RECEIPT

Mail Stop: Office of Initial Patent Examination

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

Attached is a copy of the Official Filing Receipt received from the PTO in the above application for which issuance of a corrected filing receipt is respectfully requested. Please make the correction as follows:

In the "Applicant(s)" section, please replace "Mountainview" with --Mountain View--.

The correction is not due to any error by applicant and no fee is believed to be due. However, in the event that the Patent Office determines that fees are due in connection with the filling of this document, we hereby authorize the Commissioner to charge such fees to our Deposit Account No. 07-0630.

Respectfully submitted,

GENENTECH, INC.

Date: January 23, 2004

Craig d. Svoboda

Reg. No. 39,044

Telephone No. (650) 225-1489



CGO/ER/CK

UNITED STATES DEPARTMENT OF COMMERC United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS P.O. Box 1450

O. Box 1450 Alexandria, Vinginia 22313-1450 vww.usplo.gov

FILING OR 371 APPL NO. ART UNIT FIL FEE REC'D ATTY.DOCKET NO DRAWINGS TOT CLMS IND CLMS (c) DATE 10/614,959 07/08/2003 750 1644 13 20 P1661R2C1

CONFIRMATION NO. 7129

09157 GENENTECH, INC. 1 DNA WAY SOUTH SAN FRANCISCO, CA 94080

RECEIVED

GENENTECH, INC. 125/04 LEGAL, DEPT. FILING RECEIPT

OC000000011658923

Date Mailed: 01/09/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Mountain View
Camellia W. Adams, Mountainview, CA;
Brigitte Devaux, Redwood City, CA;
Dan L. Eaton, San Rafael, CA;
Philip E. Hass, Moss Beach, CA;
J. Kevin Judice, Montara, CA;
Daniel Kirchhofer, Los Altos, CA;
Shelley Suggett, San Francisco, CA;

Assignment For Published Patent Application

Genentech, Inc.;

Domestic Priority data as claimed by applicant

This application is a CON of 09/383,667 08/26/1999 PAT 6,624,295 / which claims benefit of 60/122,767 03/03/1999 / and claims benefit of 60/098,233 08/28/1998 /

Foreign Applications

Projected Publication Date: To Be Determined - pending completion of Security Review

Non-Publication Request: No

Early Publication Request: No

Title

Human anti-factor IX/IXa antibodies <

Preliminary Class

536

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).